On October 2, 2023, the Board of Directors of FibroGen, Inc. appointed Interim Chief Executive Officer Thane Wettig as a member of the Board. Mr. Wettig was appointed as a Class I director for the term expiring at the Company?s 2024 annual meeting of stockholders. Mr. Wettig held the position of Interim Chief Executive Officer since July 23, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | +1.96% | -9.57% | +17.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.34% | 103M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FGEN Stock
- News FibroGen, Inc.
- FibroGen, Inc. Appoints Thane Wettig as a Member of the Board